EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma

Theresa Lindner iD, Viktoria Pai iD, Patrick Janku, Nikolaus Hommer, Anton Hommer, Marihan Abensperg-Traun, Liudmyla Petric, Leopold Schmetterer iD, Gerhard Garhöfer iD, Doreen Schmidl iD

Acta Ophthalmologica · 2026-03 · 104 (2) · 225-232

DOI: 10.1111/aos.17573 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Ophthalmologica, online erschienen am 07.08.2025. Verfasst von Theresa Lindner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Dronabinol, Intraocular Pressure, Glaucoma, Open-Angle, Regional Blood Flow. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Glaucoma is a leading cause of irreversible blindness globally, primarily driven by elevated intraocular pressure (IOP). Still, some patients progress despite significant IOP lowering, potentially due to impaired ocular blood flow. This study aimed to evaluate the effects of dronabinol, a synthetic tetrahydrocannabinol derivative, on ocular blood flow in primary open‐angle glaucoma (POAG) patients.

Methods

This randomized, double‐masked, placebo‐controlled, cross‐over study included 23 patients with treated POAG (mean age 68 ± 7 years). All participants received dronabinol (11 patients received 5 mg and 12 received 10 mg in a randomized fashion) on one study day and placebo on the other study day. The primary outcome was optic nerve head blood flow (ONHBF) measured by laser speckle flowgraphy. Mean blur rate was determined for the large vessel area (MV), the tissue area (MT) and the total ONH area (MA). Secondary outcomes included vessel densities assessed by optical coherence tomography angiography, IOP, and blood pressure.

Results

Administration of 10 mg dronabinol significantly increased ONHBF (MA: 10.8 ± 20.6%, p = 0.018, MV: 12.0 ± 24.8%, p = 0.042, and MT: 11.0 ± 22.6%, p = 0.022, each vs. placebo) up to 4 h post‐administration without affecting IOP or mean arterial pressure ( p > 0.548 each). Additionally, a significant increase in vessel density in the superficial vascular plexus was found after administration of 10 mg dronabinol (6.7 ± 14.7%, p = 0.040 vs. 5 mg).

Conclusion

This pilot study demonstrates that systemic dronabinol enhances ONHBF in glaucoma patients, suggesting its potential as adjunct therapy for glaucoma by targeting vascular dysfunction. Further longitudinal studies are needed to explore its long‐term impact on disease progression and visual field preservation. Trial Registration ClinicalTrials.gov ID: NCT04596826.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DronabinolIntraocular PressureGlaucoma, Open-AngleRegional Blood FlowOptic DiskHumansDouble-Blind MethodMaleFemaleAgedCross-Over StudiesAdministration, OralTomography, Optical CoherenceMiddle AgedLaser-Doppler FlowmetryBlood PressureFollow-Up StudiesBlood Flow Velocity

Stichwörter der Autor:innen

cannabinoidsdronabinol–tetrahydrocannabinolglaucomalaser speckle flowgraphyoptic nerve head blood flowoptical coherence tomography angiographyrandomized controlled clinical trialvessel densities

Substanzen

Dronabinol

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • VIROS - Vienna Institute for Research in Ocular Surgery - Karl Landsteiner Institute, Hanusch Hospital, Vienna, Austria.
  • Hommer Ophthalmology Institute, Vienna, Austria.
  • Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria.
  • Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.
  • Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore.

ORCID-Profile: Theresa Lindner, Viktoria Pai, Leopold Schmetterer, Gerhard Garhöfer, Doreen Schmidl

Förderung

  • Austrian Science Fund

Zitieren

APA

Lindner, T., Pai, V., Janku, P., Hommer, N., Hommer, A., Abensperg-Traun, M., Petric, L., Schmetterer, L., Garhöfer, G., & Schmidl, D. (2026). Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma. Acta Ophthalmologica, 104(2), 225-232. https://doi.org/10.1111/aos.17573

Vancouver

Lindner T, Pai V, Janku P, Hommer N, Hommer A, Abensperg-Traun M, et al. Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma. Acta Ophthalmologica. 2026;104(2):225-232. doi:10.1111/aos.17573

BibTeX
@article{Lindner2026,
  author = {Lindner, Theresa and Pai, Viktoria and Janku, Patrick and Hommer, Nikolaus and Hommer, Anton and Abensperg-Traun, Marihan and Petric, Liudmyla and Schmetterer, Leopold and Garhöfer, Gerhard and Schmidl, Doreen},
  title = {Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma},
  journal = {Acta Ophthalmologica},
  year = {2026},
  volume = {104},
  number = {2},
  pages = {225--232},
  doi = {10.1111/aos.17573}
}
Kostenlos starten →